Nasopharynx cancer treatment effect prediction model and application thereof

The risk score is calculated by calculating specific markers in nasopharyngeal carcinoma tissue specimens, and the problem of predicting the effect of nasopharyngeal carcinoma immunotherapy is solved, and the treatment effect of nasopharyngeal carcinoma patients is achieved is achieved, and individualized treatment is guided.

CN119044492APending Publication Date: 2024-11-29SHENZHEN JUDONG BIOMEDICAL ENG CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411050037.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-01
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The prior art is difficult to effectively predict the immunotherapy effect of nasopharyngeal carcinoma, making it difficult to determine the patient's response and prognosis during treatment.

Method used

Risk is calculated by the four markers of the tertiary lymphoid structure density, CXCL9+MECA79+ cell density, CXCR3+CD4+ T cell density, and the average distance between CXCL9+MECA79+ cells and CXCR3+CD4+ T cells in nasopharyngeal carcinoma tissue specimens, the risk is calculated Scores are used to predict the effectiveness of nasopharyngeal carcinoma immunotherapy, including complete remission, partial remission, disease stability and disease progression.

Benefits of technology

This method can accurately predict the effect of nasopharyngeal carcinoma patients after receiving immunotherapy, guide clinical medication, provide individualized treatment plans, and improve the accuracy and effectiveness of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119044492A_ABST
    Figure CN119044492A_ABST
Patent Text Reader

Abstract

The invention discloses a marker for predicting the immunotherapy effect of nasopharyngeal carcinoma, and the marker comprises the TLS density in a nasopharyngeal carcinoma tissue specimen, the CXCL9 + MECA79 + cell density, the CXCR3 + CD4 + T cell density and the average distance between the CXCL9 + MECA79 + cell and the CXCR3 + CD4 + T. The marker provided by the invention can accurately predict the immunotherapy effect of a nasopharyngeal carcinoma patient, is expected to be used for guiding clinical medication, and has a wide application prospect. And a new way is provided for accurate individualized treatment of nasopharyngeal carcinoma patients.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to a nasopharyngeal carcinoma treatment effect prediction model and application thereof. Background Art

[0002] In China, nasopharyngeal carcinoma is a common cancer, accounting for 48% of new cases of nasopharyngeal carcinoma worldwide, with a particularly high incidence in southern China. As nasopharyngeal carcinoma is insidious and early symptoms are non-specific, 75% of patients with nasopharyngeal carcinoma who are first diagnosed are in the locally advanced stage.

[0003] Immunotherapy mainly uses the effector units of the body's immune system to overcome the immune escape or adaptive immune resistance of tumors, accurately identify and eliminate tumor cells, and normalize or enhance the function of the immune system; it mainly includes cytokine therapy, immune checkpoint inhibition therapy, adoptive cell immunotherapy, tumor vaccines and antibody targeted therapy. The immune characteristics of nasopharyngeal carcinoma make patients suitable for immunotherapy or combined treatment with chemoradiotherapy. In recent years, PD-1 inhibitors alone and in combination with chemotherapy have shown good anti-tumor activity and safety in the treatment of recurrent / metastatic nasopharyngeal carcinoma. Incorporating immune checkpoint inhibitors into the treatment model of nasopharyngeal carcinoma has become a hot topic in clinical research. It is of great significance to provide markers and prediction methods that can effectively predict the efficacy of immunotherapy for nasopharyngeal carcinoma. Summary of the invention

[0004] The present invention aims to solve at least one of the above-mentioned technical problems existing in the prior art. To this end, the present invention aims to provide a nasopharyngeal carcinoma treatment effect prediction model and its application.

[0005] In order to achieve the above object, the technical solution adopted by the present invention is: The first aspect of the present invention provides markers for predicting the effect of immunotherapy for nasopharyngeal carcinoma, including: the density of tertiary lymphoid structures (TLS) in nasopharyngeal carcinoma tissue specimens, CXCL9 + MECA79 + Cell density, CXCR3 + CD4 + T cell density, CXCL9 + MECA79 + Cells and CXCR3 + CD4 + Average distance between T cells.

[0006] According to the markers provided by the present invention, it is possible to predict whether the immunotherapy for nasopharyngeal carcinoma is effective, wherein the effective treatment is defined as effective treatment according to the RECIST 1.1 standard, and the other patients are defined as ineffective treatment. CR (complete remission) is defined as: all target lesions and non-target lesions disappear, the short diameter of lymph nodes is <10mm, and no new lesions appear; PR (partial remission) is defined as: the tumor burden is reduced by ≥30% compared with the baseline, and there is no clear PD in non-target lesions; SD (stable disease) is defined as: non-PR non-PD; PD (progressive disease) is defined as: the sum of the maximum diameters increases by ≥20% (at least 5mm), or new lesions appear.

[0007] In some embodiments of the present invention, the calculation formula of the risk score of the marker for predicting the effect of immunotherapy for nasopharyngeal carcinoma is: Risk score = 2.303 × TLS density + 2.565 × CXCL9 + MECA79 + Cell density +CXCR3 + CD4 + T cell density - 21.645 × CXCL9 + MECA79 + Cells and CXCR3 + CD4 + Average distance between T cells.

[0008] In some embodiments of the present invention, the marker may also be used for at least one of the following: Predict the risk of relapse after immunotherapy; Predict the risk of metastasis after receiving immunotherapy; Predict the prognosis of the test subject after receiving immunotherapy; Predict the disease-free survival of the test subject after receiving immunotherapy; Predict the patient's survival without distant metastasis after receiving immunotherapy; Predict the overall survival of the subjects after receiving immunotherapy.

[0009] The second aspect of the present invention provides the use of a reagent in preparing a product for predicting the effect of immunotherapy for nasopharyngeal carcinoma, wherein the reagent is used to measure the TLS density, CXCL9 + MECA79 + Cell density, CXCR3 + CD4 + T cell density, CXCL9 + MECA79 + Cells and CXCR3 + CD4 + Average distance between T cells.

[0010] In some embodiments of the present invention, the reagents include determining TLS density, CXCL9 by multicolor immunofluorescence staining. + MECA79 + Cell density, CXCR3 + CD4 + T cell density, CXCL9 + MECA79 + Cells and CXCR3 + CD4 + A reagent for the average distance between T cells.

[0011] In some embodiments of the invention, the reagent comprises an opal fluorophore and an antibody.

[0012] The third aspect of the present invention provides a prediction model for the treatment effect of nasopharyngeal carcinoma, wherein the prediction model is: Risk score = 2.303 × TLS density + 2.565 × CXCL9 + MECA79 + Cell density +CXCR3 + CD4 + T cell density - 21.645 × CXCL9 + MECA79 + Cells and CXCR3 + CD4 + Average distance between T cells; Among them, TLS density, CXCL9 + MECA79 + Cell density, CXCR3 + CD4 + T cell density and CXCL9 + MECA79 + Cells and CXCR3 + CD4 + The average distance between T cells is the density of TLS and CXCL9 in nasopharyngeal carcinoma tissue specimens. + MECA79 + Cell density, CXCR3 + CD4 + T cell density, CXCL9 + MECA79 + Cells and CXCR3 + CD4 + Average distance between T cells.

[0013] In some embodiments of the present invention, if the risk score is greater than a threshold, it means that the subject is effective in receiving immunotherapy; if the risk score is less than or equal to the threshold, the subject is ineffective in receiving immunotherapy; the threshold is 25.074. Among them, effective treatment is based on the RECIST 1.1 standard, and CR and PR patients are defined as effective treatment, and others are ineffective treatment. CR (complete remission) is defined as: all target lesions and non-target lesions disappear, the short diameter of lymph nodes is <10mm, and no new lesions appear; PR (partial remission) is defined as: the tumor burden is reduced by ≥30% compared with the baseline, and there is no clear PD in non-target lesions; SD (stable disease) is defined as: non-PR non-PD; PD (disease progression) is defined as: the sum of the maximum diameters increases by ≥20% (at least 5mm), or new lesions appear.

[0014] In some embodiments of the present invention, the prediction model may also be used for at least one of the following: Predict the risk of relapse after immunotherapy; Predict the risk of metastasis after receiving immunotherapy; Predict the prognosis of the test subject after receiving immunotherapy; Predict the disease-free survival of the test subject after receiving immunotherapy; Predict the patient's survival without distant metastasis after receiving immunotherapy; Predict the overall survival of the subjects after receiving immunotherapy.

[0015] In some embodiments of the present invention, if the risk score is greater than a threshold value, it indicates that the risk of recurrence risk, metastasis risk, poor prognosis, shortened disease-free survival, shortened distant metastasis-free survival, and shortened overall survival in the subject after receiving immunotherapy is low; if the risk score is less than or equal to the threshold value, it indicates that the risk of recurrence risk, metastasis risk, poor prognosis, shortened disease-free survival, shortened distant metastasis-free survival, and shortened overall survival in the subject after receiving immunotherapy is high.

[0016] A fourth aspect of the present invention provides a detection system, comprising: a) Detection module: Collect nasopharyngeal carcinoma tissue specimens from the subjects to be tested, and measure TLS density, CXCL9 + MECA79 + Cell density, CXCR3 + CD4 + T cell density, CXCL9 + MECA79 + Cells and CXCR3 + CD4 + The average distance between T cells and the data of each marker are output to the analysis module; b) Analysis module: Calculate the risk score of the subject to be tested to predict the immunotherapy effect of the subject to be tested; The risk score is calculated as follows: Risk score = 2.303 × TLS density + 2.565 × CXCL9 + MECA79 + Cell density +CXCR3 + CD4 + T cell density - 21.645 × CXCL9 + MECA79 + Cells and CXCR3 + CD4 + Average distance between T cells; The criteria for judgment are as follows: If the risk score is greater than the threshold, it means that the immunotherapy is effective for the person being tested; If the risk score is less than or equal to the threshold, immunotherapy will be ineffective for the person being tested; c) Output module: output analysis results; The threshold is 25.074.

[0017] Among them, effective treatment is defined as effective treatment according to RECIST 1.1 standard, and CR and PR patients are defined as effective treatment, and others are ineffective treatment. CR (complete remission) is defined as: all target lesions and non-target lesions disappear, the short diameter of lymph nodes is <10mm, and no new lesions appear; PR (partial remission) is defined as: tumor burden is reduced by ≥30% compared with baseline, and non-target lesions have no clear PD; SD (stable disease) is defined as: non-PR and non-PD; PD (progressive disease) is defined as: the sum of the maximum diameters increases by ≥20% (at least 5mm), or new lesions appear.

[0018] In some embodiments of the present invention, the detection system can also be used for at least one of the following: Predict the risk of relapse after immunotherapy; Predict the risk of metastasis after receiving immunotherapy; Predict the prognosis of the test subject after receiving immunotherapy; Predict the disease-free survival of the test subject after receiving immunotherapy; Predict the patient's survival without distant metastasis after receiving immunotherapy; Predict the overall survival of the subjects after receiving immunotherapy.

[0019] In some embodiments of the present invention, if the risk score is greater than a threshold value, it indicates that the risk of recurrence risk, metastasis risk, poor prognosis, shortened disease-free survival, shortened distant metastasis-free survival, and shortened overall survival in the subject after receiving immunotherapy is low; if the risk score is less than or equal to the threshold value, it indicates that the risk of recurrence risk, metastasis risk, poor prognosis, shortened disease-free survival, shortened distant metastasis-free survival, and shortened overall survival in the subject after receiving immunotherapy is high.

[0020] A fifth aspect of the present invention provides a computing device, comprising: at least one processing unit; and At least one memory, the memory is coupled to the processing unit and stores instructions for execution by the processing unit, and when the instructions are executed, the device can predict the immunotherapy effect of nasopharyngeal carcinoma patients, and the prediction includes the following steps: (a) Based on the collected and measured TLS density and CXCL9 in the nasopharyngeal carcinoma tissue specimens of the subjects + MECA79 + Cell density, CXCR3 + CD4 + T cell density, CXCL9 + MECA79 + Cells and CXCR3 + CD4 + The average distance between T cells is used to calculate the risk score of the person being tested; The risk score is calculated as follows: Risk score = 2.303 × TLS density + 2.565 × CXCL9 + MECA79 + Cell density +CXCR3 + CD4 + T cell density - 21.645 × CXCL9 + MECA79 + Cells and CXCR3 + CD4 + Average distance between T cells; (b) predicting the immunotherapy effect of the subject according to the risk score of the subject; The criteria for judgment are as follows: If the risk score is greater than the threshold, it means that the immunotherapy is effective for the person being tested; If the risk score is less than or equal to the threshold, immunotherapy will be ineffective for the person being tested; The threshold is 25.074.

[0021] Among them, effective treatment is defined as effective treatment according to RECIST 1.1 standard, and CR and PR patients are defined as effective treatment, and others are ineffective treatment. CR (complete remission) is defined as: all target lesions and non-target lesions disappear, the short diameter of lymph nodes is <10mm, and no new lesions appear; PR (partial remission) is defined as: tumor burden is reduced by ≥30% compared with baseline, and non-target lesions have no clear PD; SD (stable disease) is defined as: non-PR and non-PD; PD (progressive disease) is defined as: the sum of the maximum diameters increases by ≥20% (at least 5mm), or new lesions appear.

[0022] In some embodiments of the present invention, the computing device may also be used for at least one of the following: Predict the risk of relapse after immunotherapy; Predict the risk of metastasis after receiving immunotherapy; Predict the prognosis of the test subject after receiving immunotherapy; Predict the disease-free survival of the test subject after receiving immunotherapy; Predict the patient's survival without distant metastasis after receiving immunotherapy; Predict the overall survival of the subjects after receiving immunotherapy.

[0023] In some embodiments of the present invention, if the risk score is greater than a threshold value, it indicates that the risk of recurrence risk, metastasis risk, poor prognosis, shortened disease-free survival, shortened distant metastasis-free survival, and shortened overall survival in the subject after receiving immunotherapy is low; if the risk score is less than or equal to the threshold value, it indicates that the risk of recurrence risk, metastasis risk, poor prognosis, shortened disease-free survival, shortened distant metastasis-free survival, and shortened overall survival in the subject after receiving immunotherapy is high.

[0024] A sixth aspect of the present invention provides a computer-readable storage medium storing a computer program, which can be executed by a machine to implement the steps of predicting the effect of immunotherapy on nasopharyngeal carcinoma patients, the steps being as follows: (a) Based on the collected and measured TLS density and CXCL9 in the nasopharyngeal carcinoma tissue specimens of the subjects + MECA79 + Cell density, CXCR3 + CD4 + T cell density, CXCL9 + MECA79 + Cells and CXCR3 + CD4 + The average distance between T cells is used to calculate the risk score of the person being tested; The risk score is calculated as follows: Risk score = 2.303 × TLS density + 2.565 × CXCL9+ MECA79 + Cell density +CXCR3 + CD4 + T cell density - 21.645 × CXCL9 + MECA79 + Cells and CXCR3 + CD4 + Average distance between T cells; (b) predicting the immunotherapy effect of the subject according to the risk score of the subject; The criteria for judgment are as follows: If the risk score is greater than the threshold, it means that the immunotherapy is effective for the person being tested; If the risk score is less than or equal to the threshold, immunotherapy will be ineffective for the person being tested; The threshold is 25.074.

[0025] In some embodiments of the present invention, the computer-readable storage medium may also be used for at least one of the following: Predict the risk of relapse after immunotherapy; Predict the risk of metastasis after receiving immunotherapy; Predict the prognosis of the test subject after receiving immunotherapy; Predict the disease-free survival of the test subject after receiving immunotherapy; Predict the patient's survival without distant metastasis after receiving immunotherapy; Predict the overall survival of the subjects after receiving immunotherapy.

[0026] In some embodiments of the present invention, if the risk score is greater than a threshold value, it indicates that the risk of recurrence risk, metastasis risk, poor prognosis, shortened disease-free survival, shortened distant metastasis-free survival, and shortened overall survival in the subject after receiving immunotherapy is low; if the risk score is less than or equal to the threshold value, it indicates that the risk of recurrence risk, metastasis risk, poor prognosis, shortened disease-free survival, shortened distant metastasis-free survival, and shortened overall survival in the subject after receiving immunotherapy is high.

[0027] The beneficial effects of the present invention are as follows: the present invention provides markers for predicting the effect of immunotherapy for nasopharyngeal carcinoma, including TLS density, CXCL9 in nasopharyngeal carcinoma tissue specimens, + MECA79 + Cell density, CXCR3 + CD4 + T cell density, CXCL9 + MECA79 + Cells and CXCR3 + CD4 +The marker-based prediction model of the present invention can accurately predict the effect of immunotherapy on nasopharyngeal carcinoma patients, and is expected to be used to guide clinical medication, providing a new approach for precise individualized treatment of nasopharyngeal carcinoma patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 The relationship between each prognostic marker and prognosis in Kaplan-Meier survival analysis; Figure 2 Univariate Cox analysis was used to screen the independent influencing factors of prognosis in patients with nasopharyngeal carcinoma; Figure 3 Immunotherapy effect prediction model; Figure 4 The optimal cutoff value of the model was determined based on the ROC curve; Figure 5 Use the immunotherapy effect prediction model to predict the efficacy of patients in the training set and validation set; Figure 6 Validation set ROC curve. DETAILED DESCRIPTION

[0029] The present invention is further described in detail below by specific examples. Unless otherwise specified, the raw materials, reagents or devices used in the examples and comparative examples can be obtained from conventional commercial sources or can be obtained by prior art methods. Unless otherwise specified, the experiments or test methods are conventional methods in the art.

[0030] In the embodiment of the present invention, 135 patients with nasopharyngeal carcinoma who were admitted to the Affiliated Cancer Hospital of Sun Yat-sen University from January 2014 to July 2015 were selected; 59 patients who were admitted to the Affiliated Cancer Hospital of Sun Yat-sen University and received immunotherapy from December 2018 to August 2019 were collected. Immunotherapy refers to treatment with pembrolizumab, cisplatin and 5-FU. The data of 30 patients with nasopharyngeal carcinoma were included to establish an immunotherapy effect prediction model (training set), and 29 patients with nasopharyngeal carcinoma (validation set) were included to verify the prediction model.

[0031] Inclusion criteria: (1) The postoperative pathological diagnosis was nasopharyngeal carcinoma and the patient's medical records were complete; (2) no anti-tumor treatment such as chemoradiotherapy, biological therapy or immunotherapy was performed before surgery; (3) complete survival follow-up data were available.

[0032] Exclusion criteria: (1) patients with other types of malignant tumors within 5 years; (2) patients with metastasis from other tumors; (3) patients who received anti-tumor treatment before surgery. Overall survival (OS) was defined as the duration from the first surgery to death or the last follow-up. Progression-free survival (PFS) was defined as the time from the first surgery to tumor progression (in any aspect) or death due to any cause.

[0033] Example 1 Establishment of a model to predict the effect of immunotherapy 1. Multicolor immunofluorescence staining Formalin-fixed, paraffin-embedded nasopharyngeal carcinoma tissue specimens were collected to construct tissue microarrays. The sections were dewaxed, rinsed with distilled water, and then antigen retrieval was performed. After that, the slides were cooled to room temperature. Then, 5% BSA was used for blocking at room temperature for 1 hour. Then the primary antibody was added, incubated at 4°C overnight, and washed with PBS for 5 minutes × 3 times; horseradish peroxidase-conjugated secondary antibody was incubated at room temperature for 15 minutes, and then opal (Opal) fluorophore was incubated continuously at room temperature for 15 minutes. Staining included multiple cycles of antigen retrieval, cooling, blocking, incubation of primary antibody, secondary antibody and opal fluorophore; the cycle was repeated until all markers were stained. Finally, DAPI was used to stain the nucleus. The staining in this study was performed using serial sections in the following order: Solution 1: CD20 (1:200) (identify TLS area by CD20 staining); Scheme 2: CXCL9 (1:200), MECA79 (1:200), CXCR3 (1:200), CD4 (1:200).

[0034] The primary and secondary antibodies used were as follows:

[0035] 2. Analysis of staining results Tissue sections were visualized and analyzed using HALO Pathology Analysis Software (Indica Labs). Spectral unmixing was applied to distinguish different fluorescent signals. For each slide, the total cell number was calculated and different cell phenotypes (TLS, CXCL9, + Cells, MECA79 + Cells, CXCR3 + cells, CD4 + T cells, CXCL9 + MECA79 + Cells, CXCR3 + CD4 + T cells) and record the spatial location of the cells.

[0036] After project analysis, calculate TLS, CXCL9+ HEV cells (CXCL9 + MECA79 + )、CXCR3 + CD4 + T cells (CXCR3 + CD4 + ) number and area. + MECA79 + Cells, CXCR3 + CD4 + T cells were phenotyped and CXCL9 was detected + MECA79 + Cells and CXCR3 + CD4 + The average distance between T cells.

[0037] 3. Data Analysis The Kaplan-Meier method was used to analyze the prognosis of patients. Univariate and multivariate Cox regression analyses were used to screen independent prognostic factors. A prognostic nomogram was constructed to evaluate the probability of 1-year overall survival (OS) of NPC patients.

[0038] The model uses LASSO regression to screen relevant risk factors, and the formula for establishing the risk score model is as follows: risk score = influencing factor 1×β1+influencing factor 2×β2+…+influencing factor n×βn; among them, β is the regression coefficient calculated by multivariate Cox regression.

[0039] 4. Results 4.1 Screening of prognostic factors using univariate cox regression Kaplan-Meier survival analysis was performed to analyze TLS density, CXCL9 + Cell density, MECA79 + Cell density, CXCR3 + Cell density, CD4 + T cell density, CXCL9 + MECA79 + Cell density, CXCR3 + CD4 + T cell density and CXCL9 + MECA79 + Cells and CXCR3 + CD4 + The relationship between the average distance between T cells and patient prognosis was found to be high in TLS density and CXCL9 + High cell density, MECA79 + High cell density, CXCR3+ High cell density, CD4 + High T cell density, CXCL9 + MECA79 + High cell density, CXCR3 + CD4 + High T cell density and CXCL9 + MECA79 + Cells and CXCR3 + CD4 + Patients with a shorter average distance between T cells had a better prognosis ( Figure 1 ).

[0040] Subsequently, the TNM staging of NPC patients (adopting the UICC / AJCC TNM staging system, where T stage represents the extent of the primary tumor, N stage represents the presence or absence of regional lymph node metastasis, and M stage represents the presence or absence of distant metastasis), clinical characteristics such as age and gender, and TLS density, CXCL9 + Cell density, MECA79 + Cell density, CXCR3 + Cell density, CD4 + T cell density, CXCL9 + MECA79 + Cell density, CXCR3 + CD4 + T cell density and CXCL9 + MECA79 + Cells and CXCR3 + CD4 + The average distance between T cells. Screening by univariate Cox regression analysis ( Figure 2 ), the results showed that the density of TLS and CXCL9 in tissues + MECA79 + Cell density, CXCR3 + CD4 + T cell density and CXCL9 + MECA79 + Cells and CXCR3 + CD4 + The average distance between T cells is an independent factor affecting the prognosis of patients with nasopharyngeal carcinoma.

[0041] 4.2 Establishment of a prediction model for immunotherapy effects Based on the independent influencing factors of patient prognosis, 30 patient data (training set) were included to establish an immunotherapy effect prediction model: risk score = 2.303 × TLS density + 2.565 × CXCL9 + MECA79+ Cell density +CXCR3 + CD4 + T cell density - 21.645 × CXCL9 + MECA79 + Cells and CXCR3 + CD4 + The average distance between T cells ( Figure 3 ).

[0042] According to the ROC curve, the optimal cutoff value of the model was determined to be 25.074 ( Figure 4 ), when the patient's CTR-score is greater than 25.074, it indicates that immunotherapy is likely to be effective; when the patient's CTR-score is less than or equal to 25.074, it indicates that immunotherapy is likely to be ineffective. Effective treatment is based on the RECIST 1.1 standard, and CR and PR patients are defined as effective treatment, and others are ineffective. CR (complete remission) is defined as: all target lesions and non-target lesions disappear, the short diameter of lymph nodes is <10mm, and no new lesions appear; PR (partial remission) is defined as: tumor burden is reduced by ≥30% compared with baseline, and there is no clear PD in non-target lesions; SD (stable disease) is defined as: non-PR non-PD; PD (progressive disease) is defined as: the sum of the maximum diameters increases by ≥20% (at least 5mm), or new lesions appear.

[0043] Example 2 Validation of the immunotherapy effect prediction model The immunotherapy effect prediction model obtained in Example 1 was used to verify the efficacy prediction effect of the training set (30 nasopharyngeal carcinoma patients) and the validation set (29 nasopharyngeal carcinoma patients). The results are as follows: Figure 5 As shown in the figure, in the training set, the patients predicted to have high CTR-scores were all effective in immunotherapy, while 75% of the patients with low CTR-scores were ineffective in immunotherapy; in the validation set, 90.9% of the patients predicted to have high CTR-scores were effective in immunotherapy, while 77.78% of the patients with low CTR-scores were ineffective in immunotherapy; through the analysis of the validation set and the training set, it was found that the model had good predictive efficiency. The area under the ROC curve (AUC) of the validation set reached 0.790 ( Figure 6 ), which can better predict the efficacy of immunotherapy in patients with NPC.

[0044] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. Predictive markers for nasopharyngeal carcinoma treatment efficacy, including: TLS density and CXCL9 in nasopharyngeal carcinoma tissue specimens + MECA79 + Cell density, CXCR3 + CD4 + T cell density, CXCL9 + MECA79 + Cells and CXCR3 + CD4 + The average distance between T cells; the treatment is immunotherapy.

2. The marker according to claim 1, characterized in that The calculation formula of the risk score of the marker for predicting the effect of immunotherapy for nasopharyngeal carcinoma is: Risk score = 2.303 × TLS density + 2.565 × CXCL9 + MECA79 + Cell density +CXCR3 + CD4 + T cell density - 21.645 × CXCL9 + MECA79 + Cells and CXCR3 + CD4 + Average distance between T cells.

3. The marker according to claim 1, characterized in that The marker may also be used for at least one of the following: Predict the risk of relapse after immunotherapy; Predict the risk of metastasis after receiving immunotherapy; Predict the prognosis of the test subject after receiving immunotherapy; Predict the disease-free survival of the test subject after receiving immunotherapy; Predict the patient's survival without distant metastasis after receiving immunotherapy; Predict the overall survival of the subjects after receiving immunotherapy.

4. Application of the reagent in the preparation of a product for predicting the therapeutic effect of nasopharyngeal carcinoma, wherein the reagent is used to determine the TLS density, CXCL9 + MECA79 + Cell density, CXCR3 + CD4 + T cell density, CXCL9 + MECA79 + Cells and CXCR3 + CD4 + The average distance between T cells; the treatment is immunotherapy.

5. The use according to claim 4, characterized in that: The reagents include multicolor immunofluorescence staining to determine TLS density, CXCL9 + MECA79 + Cell density, CXCR3 + CD4 + T cell density, CXCL9 + MECA79 + Cells and CXCR3 + CD4 + A reagent for the average distance between T cells.

6. The use according to claim 4, characterized in that: The reagents include an opal fluorophore and an antibody.

7. A prediction model for the treatment effect of nasopharyngeal carcinoma, wherein the prediction model is: Risk score = 2.303 × TLS density + 2.565 × CXCL9 + MECA79 + Cell density +CXCR3 + CD4 + T cell density - 21.645 × CXCL9 + MECA79 + Cells and CXCR3 + CD4 + Average distance between T cells; in, TLS density, CXCL9 + MECA79 + Cell density, CXCR3 + CD4 + T cell density and CXCL9 + MECA79 + Cells and CXCR3 + CD4 + The average distance between T cells is the density of TLS and CXCL9 in nasopharyngeal carcinoma tissue specimens. + MECA79 + Cell density, CXCR3 + CD4 + T cell density, CXCL9 + MECA79 + Cells and CXCR3 + CD4 + Average distance between T cells; The treatment is immunotherapy.

8. A detection system comprising: a) Detection module: collect nasopharyngeal carcinoma tissue specimens from the subjects, TLS density, CXCL9 + MECA79 + Cell density, CXCR3 + CD4 + T cell density, CXCL9 + MECA79 + Cells and CXCR3 + CD4 + The average distance between T cells and the data of each marker are output to the analysis module; b) Analysis module: Calculate the risk score of the subject to be tested to predict the immunotherapy effect of the subject to be tested; The risk score is calculated as follows: Risk score = 2.303 × TLS density + 2.565 × CXCL9 + MECA79 + Cell density +CXCR3 + CD4 + T cell density - 21.645 × CXCL9 + MECA79 + Cells and CXCR3 + CD4 + Average distance between T cells; The criteria for judgment are as follows: If the risk score is greater than the threshold, it means that the immunotherapy is effective for the person being tested; If the risk score is less than or equal to the threshold, immunotherapy will be ineffective for the person being tested; c) Output module: output analysis results; The threshold is 25.

074.

9. A computing device comprising: at least one processing unit; and At least one memory, the memory is coupled to the processing unit and stores instructions for execution by the processing unit, and when the instructions are executed, the device can predict the immunotherapy effect of nasopharyngeal carcinoma patients, and the prediction includes the following steps: (a) Based on the collected and measured TLS density and CXCL9 in the nasopharyngeal carcinoma tissue specimens of the subjects + MECA79 + Cell density, CXCR3 + CD4 + T cell density, CXCL9 + MECA79 + Cells and CXCR3 + CD4 + The average distance between T cells is used to calculate the risk score of the person being tested; The risk score is calculated as follows: Risk score = 2.303 × TLS density + 2.565 × CXCL9 + MECA79 + Cell density +CXCR3 + CD4 + T cell density - 21.645 × CXCL9 + MECA79 + Cells and CXCR3 + CD4 + Average distance between T cells; (b) predicting the immunotherapy effect of the subject according to the risk score of the subject; The criteria for judgment are as follows: If the risk score is greater than the threshold, it means that the immunotherapy is effective for the person being tested; If the risk score is less than or equal to the threshold, immunotherapy will be ineffective for the person being tested; The threshold is 25.

074.

10. A computer-readable storage medium storing a computer program, which can be executed by a machine to implement the steps of predicting the effect of immunotherapy on nasopharyngeal carcinoma patients, the steps being as follows: (a) Based on the collected and measured TLS density and CXCL9 in the nasopharyngeal carcinoma tissue specimens of the subjects + MECA79 + Cell density, CXCR3 + CD4 + T cell density, CXCL9 + MECA79 + Cells and CXCR3 + CD4 + The average distance between T cells is used to calculate the risk score of the person being tested; The risk score is calculated as follows: Risk score = 2.303 × TLS density + 2.565 × CXCL9 + MECA79 + Cell density +CXCR3 + CD4 + T cell density - 21.645 × CXCL9 + MECA79 + Cells and CXCR3 + CD4 + Average distance between T cells; (b) predicting the immunotherapy effect of the subject according to the risk score of the subject; The criteria for judgment are as follows: If the risk score is greater than the threshold, it means that the immunotherapy is effective for the person being tested; If the risk score is less than or equal to the threshold, immunotherapy will be ineffective for the person being tested; The threshold is 25.074.

Citation Information

Cited By

  • Biomarker for prognosis evaluation of recurrent nasopharyngeal carcinoma patient and application thereof

    CN120490485A